Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Single Center, Single Patient Study of an Experimental Antisense Oligonucleotide (ASO) Treatment in AA Amyloidosis

NCT06397001 is registered in ClinicalTrials.gov with Nelson Leung, MD as lead sponsor.

NCT NCT06397001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06397001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Single Center, Single Patient Study of an Experimental Antisense Oligonucleotide (ASO) Treatment in AA Amyloidosis
Lead sponsor
Nelson Leung, MD
Phase
Phase 1
Overall status
Completed
Start date
November 28, 2023
Completion date
December 2, 2024
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aa amyloidosis